UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
|
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
Date of report (Date of earliest event reported): February 25, 2004 |
|
CORE LABORATORIES N.V.
(Exact name of Registrant as specified in its charter)
Commission File Number 001-14273
The Netherlands |
Not Applicable |
(State or other jurisdiction of Incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
Herengracht 424 |
|
1017 BZ Amsterdam |
|
The Netherlands |
Not Applicable |
(Address of principal executive offices) |
(Zip Code) |
|
|
Registrant's telephone number, including area code: (31-20) 420-3191
Item 7. Financial Statements and Exhibits.
|
(a) |
|
Financial statements: None. |
|
|
||||
|
(b) |
|
Pro forma financial information: None. |
|
|
||||
|
(c) |
|
Exhibits: |
|
|
|
|
Exhibit 99 |
|
Press release dated February 25, 2004. |
Item 12. Disclosure of Results of Operations and Financial Condition.
On February 25, 2004, Core Laboratories, N.V. issued a press release announcing its 2003 fourth quarter and fiscal year end financial results. The full text of the press release is set forth in Exhibit 99 attached hereto and is incorporated in this Report as if fully set forth herein.
The information in this Form 8-K shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in the Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Core Laboratories, N.V. |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: February 25, 2004 |
|
By |
|
/s/ Richard L. Bergmark |
|
|
|
|
|
|
Richard L. Bergmark |
|
|
|
|
|
|
Chief Financial Officer |
|
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CORE LABORATORIES, N.V.
EXHIBIT INDEX TO FORM 8-K
|
|
|
EXHIBIT NO. |
|
ITEM |
|
|
|
99 |
|
Press Release dated February 25, 2004 |